Feasibility and cost-benefit of implementing pooled screening for HCVAg in small blood bank settings

Transfusion Medicine

Volumn 17, Issue 6, 2007, Pages 479-487

  Sarov, B ^a   Novack, L ^a,b   Beer, N ^a   Safi, J ^c   Soliman, H ^c   Pliskin, J S ^a   Litvak, E ^d   Yaari, A ^e   Shinar, E ^f  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c Environmental Protection and Research Institute   (Palestine)

^d BOSTON UNIVERSITY   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f MAGEN DAVID ADOM   (Israel)

Author keywords

Blood donors; Cost benefit; HCVAg; Pooled testing

Indexed keywords

CORE PROTEIN;

ARTICLE; BLOOD BANK; BLOOD DONOR; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HEPATITIS C VIRUS; HUMAN; INCIDENCE; NONHUMAN; POLYMERASE CHAIN REACTION; SCREENING; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD BANKS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DONOR SELECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS; ISRAEL; POLYMERASE CHAIN REACTION; RISK REDUCTION BEHAVIOR; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 36649029961     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2007.00790.x     Document Type: Article

References (25)

1. Beer, N., Shinar, E., Novack, L. et al 2006) Accuracy of HCV-Ag testing in pools among seroconverters. Transfusion, 46, 1822 1828.
2. Brooks, G.F., Butel, J.S., Morse, S.A. Jawetz, E 2001) Jawetz, Melnick, & Adelberg's Medical Microbiology (22nd edn ix, 694. Lange Medical Books/McGraw-Hill Medical Pub Division, New York.
3. Courouce, A.M., Le Marrec, N., Bouchardeau, F., Razer, A., Maniez, M., Laperche, S. Simon, N 2000) Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion, 40, 1198 1202.
4. Dienstag, J. Isselbacher, K 2001) Acute viral hepatitis. In: Harrison's Principles of Internal Medicine (eds Braunwald, E., Fausi, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L. Jameson, J.L. 721 737. McGraw-Hill, New York.
5. Dodd, R.Y 2004) Current safety of the blood supply in the United States. International Journal of Hematology, 80, 301 305.
6. Dodd, R.Y., Notari, E.P. Stramer, S.L 2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42, 975 979.
7. Drummond, M.F., Stoddart, G.L. Torrance, G.W 1987) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford [Oxfordshire].
8. Hmaied, F., Arrouji, Z., Slim, A. Ben Redjeb, S 2007) Use of combined detection of hepatitis C virus core antigen and antibodies to reduce the serological window-phase. Pathology Biology, 55, 122 126.
9. Icardi, G., Ansaldi, F., Bruzzone, B.M., Durando, P., Lee, S., de Luigi, C. Crovari, P 2001) Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. Journal of Clinical Microbiology, 39, 3110 3114.
10. Israel National Center for Transplantations ('Adi'). URL www.health.gov.il/transplant/ accessed 8 August 2007 Gross, J. Jr. 1997) Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Annals of Internal Medicine, 127, 866 874.
11. Laperche, S., Elghouzzi, M.H., Morel, P. et al 2005a) Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion, 45, 1965 1972.
12. Laperche, S., Le Marrec, N., Girault, A. et al 2005b) Simultaneous detection of hepatitis C virus(HCV) core antigen and anti HCV antibodies improves the early detection of HCV infection. Journal of Clinical Microbiology, 43, 3877 3883.
13. Lee, S.R., Peterson, J., Niven, P. et al 2001) Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations. Vox Sanguinis, 80, 19 23.
14. Letowska, M., Brojer, E., Mikulska, M., Gronowska, A. Rosiek, A 2004) Hepatitis C core antigen in Polish blood donors. Transfusion, 44, 1067 1071.
15. Nubling, C.M., Unger, G., Chudy, M., Raia, S. Lower, J 2002) Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion, 42, 1037 1045.
16. Pereira, A 2000) A model of the health and economic impact of posttransfusion hepatitis C: application of cost-effectiveness analysis further expansion of HCV screening protocols. Transfusion, 40, 1182 1191.
17. Peterson, J., Green, G., Iida, K., Caldwell, B., Kerrison, P., Bernich, S., Aoyagi, K. Lee, S.R 2000) Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection. Vox Sanguinis, 78, 80 85.
18. Pomper, G.J., Wu, Y. Snyder, E.L 2003) Risks of transfusion-transmitted infections: 2003. Current Opinion in Hematology, 10, 412 418.
19. Sarov, B., Novack, L., Galai, N. et al 2007) Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on sero convertion panels. Clinical Microbiology and Infection, 13, 737 739.
20. Scitovsky, A.A. Over, M 1988) AIDS: costs of care in the developed and the developing world. AIDS, 2 (Suppl. 1 S71 S81.
21. Shinar, E., Yahalom, V., Peterson, L.J. et al 2001) HCV-Ag testing in Israeli blood donors. Transfusion, 41 (Suppl 77S.
22. Stramer, S.L., Glynn, S.A., Kleinman, S.H. et al 2004) Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. New England Journal of Medicine, 351, 760 768.
23. Vamvakas, E.C. Taswell, H.F 1994) Long-term survival after blood transfusion. Transfusion, 34, 471 477.
24. Wong, J.B., Bennett, W.G., Koff, R.S. Pauker, S.G 1998) Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. Journal of the American Medical Association, 280, 2088 2093.
25. World Health Organization. URL http://www.who.int/ diagnostics_labENGLoratory/evaluations/en/hcv_rep2.pdf accessed 8 August 2007]. Hepatitis C Assays, Operational Characteristics (Phase 1), July 2001.